Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia

American Journal of Health-System Pharmacy

Volumn 65, Issue 2, 2008, Pages 150-153

  Wall, Geoffrey C ^a,b   Pauly, Rebecca A ^c  

^a IOWA METHODIST MEDICAL CENTER   (United States)

^b DRAKE UNIVERSITY   (United States)

^c Chandler Regional Medical Center   (United States)

Author keywords

Anemia; Dosage; Injections; Iron preparations; Iron sucrose; Toxicity

Indexed keywords

FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; TRANSFERRIN;

ADULT; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENDER; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; MALE; MEAN CORPUSCULAR VOLUME; NAUSEA; OUTCOME ASSESSMENT; PARAMETER; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; TACHYCARDIA; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TRANSFERRIN SATURATION;

EID: 38349016976     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070222     Document Type: Article

References (18)

1. Iron deficiency - United States, 1999-2000. MMWR Morb Mortal Wkly Rep. 2002; 51:897-9.
2. Johnson-Spear MA, Yip R. Hemoglobin difference between black and white women with comparable iron status: justification for race-specific anemia criteria. Am J Clin Nutr. 1994; 60:117-21.
3. Waldmann A, Koschizke JW, Leitzmann C et al. German vegan study: diet, life-style factors, and cardiovascular risk profile. Ann Nutr Metab. 2005; 49:366-72.
4. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther. 2001; 23:1637-71.
5. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004; 97:887-9.
6. Kumpf VJ, Holland EG. Parenteral iron dextran therapy. DICP. 1990; 24:162-6.
7. Chertow GM, Mason PD, Vaage-Nilsen O et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21:378-82.
8. Venofer (Iron Sucrose Injection, USP) product information. Shirley, NY: American Regent Laboratory; 2006.
9. InFeD (Iron Dextran Injection, USP) product information. Corona, CA: Watson Pharmaceuticals; 2004.
10. Ravel R. Clinical laboratory medicine, 6th ed. St. Louis: Mosby-YearBook; 1995:9-11.
11. Schwenk MH, Blaustein DA. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney disease. Clin Nephrol. 2004; 62:116-20.
12. Al-Hawas F, Abdalla AH, Popovich W et al. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. Nephrol Dial Transplant. 1997; 12:2801-2.
13. Blaustein DA, Schwenk MH, Chattopadhyay J et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl. 2003; 87:S72-7.
14. Legssyer R, Geisser P, McArdle H et al. Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. BioMetals. 2003; 16:425-33.
15. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004; 15:S93-8.
16. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38:988-91.
17. Blaustein DA, Schwenk MH, Chattopadhyay J et al. Recent experience with high-dose intravenous iron administration. Kidney Int Suppl. 2006; 104:S26-9.
18. Hollands JM, Foote EF, Rodriguez A et al. Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease. Am J Health-Syst Pharm. 2006; 63:731-4.